Dr. Thomas Pesnot joined the company in 2017 as a Group Leader and was promoted to Head of Medicinal Chemistry in 2021. He has gained over 15 years' experience of leading drug discovery programmes in the academic, biotech and CRO sectors, and contributed to the development of multiple clinical candidates and marketed drugs.

His scientific expertise spans a wide range of therapeutic areas (oncology, immuno-oncology, fibrosis and neurosciences) and target classes (kinases, enzymes, GPCRs, ion channels) at all stages of the drug discovery process. A Fellow of the Royal Society of Chemistry, Thomas has authored over 35 publications, reviews and patents in the field of drug discovery, synthetic chemistry and enzymology.